CF PharmTech Launches Up to HK$608 Million Hong Kong IPO

MT Newswires Live

Sep 26

CF PharmTech (HKG:2652) launched its initial public offering in Hong Kong on Friday, seeking to raise up to HK$607.7 million from the deal.

The inhalation drug developer expects to price the offering of as many as 41,198,000 shares at HK$14.75 apiece, according to an early Friday morning filing with the Hong Kong Stock Exchange.

Allocation results are anticipated to be disclosed on Oct. 6, ahead of the company's trading debut on the bourse on Oct. 8.

Net proceeds of approximately HK$525.4 million are earmarked for funding the ongoing R&D and clinical development of the company's inhalation formulation product candidates, as well as the pre-clinical R&D of its multiple other pipeline programs and technologies. The funds will also support facilities expansion and upgrade, as well as working capital and other general corporate purposes.

CITIC Securities (Hong Kong) and CMB International Capital are the joint sponsors of the offering. The two also act as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers together with CCB International Capital.

Meanwhile, CLSA Limited, Soochow Securities International Brokerage, Shenwan Hongyuan Securities (H.K.), SPDB International Capital, SDICS International Securities (Hong Kong), ICBC International Securities, Central China International Securities, BOCOM International Securities, ABCI Capital, and Guosen Securities (HK) Brokerage were tapped as joint bookrunners and joint lead managers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2570233700"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2570233700\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2570233700?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-26 08:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570233700","market":"fut","top_or_hot":-1,"title":"CF PharmTech Launches Up to HK$608 Million Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> CF PharmTech (HKG:2652) launched its initial public offering in Hong Kong on Friday, seeking to raise up to HK$607.7 million from the deal.</p><p>The inhalation drug developer expects to price the offering of as many as 41,198,000 shares at HK$14.75 apiece, according to an early Friday morning filing with the Hong Kong Stock Exchange.</p><p>Allocation results are anticipated to be disclosed on Oct. 6, ahead of the company's trading debut on the bourse on Oct. 8.</p><p>Net proceeds of approximately HK$525.4 million are earmarked for funding the ongoing R&amp;D and clinical development of the company's inhalation formulation product candidates, as well as the pre-clinical R&amp;D of its multiple other pipeline programs and technologies. The funds will also support facilities expansion and upgrade, as well as working capital and other general corporate purposes.</p><p>CITIC Securities (Hong Kong) and CMB International Capital are the joint sponsors of the offering. The two also act as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers together with CCB International Capital.</p><p>Meanwhile, CLSA Limited, <a href=\"https://laohu8.com/S/601555\">Soochow Securities</a> International Brokerage, <a href=\"https://laohu8.com/S/SHHGF\">Shenwan Hongyuan</a> Securities (H.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.), SPDB International Capital, SDICS International Securities (Hong Kong), ICBC International Securities, <a href=\"https://laohu8.com/S/00832\">Central China</a> International Securities, BOCOM International Securities, ABCI Capital, and <a href=\"https://laohu8.com/S/002736\">Guosen Securities</a> (HK) Brokerage were tapped as joint bookrunners and joint lead managers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PharmTech Launches Up to HK$608 Million Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PharmTech Launches Up to HK$608 Million Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-26 08:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> CF PharmTech (HKG:2652) launched its initial public offering in Hong Kong on Friday, seeking to raise up to HK$607.7 million from the deal.</p><p>The inhalation drug developer expects to price the offering of as many as 41,198,000 shares at HK$14.75 apiece, according to an early Friday morning filing with the Hong Kong Stock Exchange.</p><p>Allocation results are anticipated to be disclosed on Oct. 6, ahead of the company's trading debut on the bourse on Oct. 8.</p><p>Net proceeds of approximately HK$525.4 million are earmarked for funding the ongoing R&amp;D and clinical development of the company's inhalation formulation product candidates, as well as the pre-clinical R&amp;D of its multiple other pipeline programs and technologies. The funds will also support facilities expansion and upgrade, as well as working capital and other general corporate purposes.</p><p>CITIC Securities (Hong Kong) and CMB International Capital are the joint sponsors of the offering. The two also act as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers together with CCB International Capital.</p><p>Meanwhile, CLSA Limited, <a href=\"https://laohu8.com/S/601555\">Soochow Securities</a> International Brokerage, <a href=\"https://laohu8.com/S/SHHGF\">Shenwan Hongyuan</a> Securities (H.<a href=\"https://laohu8.com/S/TKKD.SI\">K</a>.), SPDB International Capital, SDICS International Securities (Hong Kong), ICBC International Securities, <a href=\"https://laohu8.com/S/00832\">Central China</a> International Securities, BOCOM International Securities, ABCI Capital, and <a href=\"https://laohu8.com/S/002736\">Guosen Securities</a> (HK) Brokerage were tapped as joint bookrunners and joint lead managers.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4093","symbol_name":"化肥与农用药剂","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2570233700","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570233700","pubTimestamp":1758844986,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"CF PharmTech (HKG:2652) launched its initial public offering in Hong Kong on Friday, seeking to raise up to HK$607.7 million from the deal.The inhalation drug developer expects to price the offering o","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4093":"化肥与农用药剂","BK4588":"碎股","01398":"工商银行","00939":"建设银行","BK4585":"ETF&股票定投概念","CF":"CF工业"},"translate_title":"CF PharmTech启动高达6.08亿港元的香港IPO","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00939":0.6,"01398":0.6,"CF":1.5},"content_text":"CF PharmTech (HKG:2652) launched its initial public offering in Hong Kong on Friday, seeking to raise up to HK$607.7 million from the deal.The inhalation drug developer expects to price the offering of as many as 41,198,000 shares at HK$14.75 apiece, according to an early Friday morning filing with the Hong Kong Stock Exchange.Allocation results are anticipated to be disclosed on Oct. 6, ahead of the company's trading debut on the bourse on Oct. 8.Net proceeds of approximately HK$525.4 million are earmarked for funding the ongoing R&D and clinical development of the company's inhalation formulation product candidates, as well as the pre-clinical R&D of its multiple other pipeline programs and technologies. The funds will also support facilities expansion and upgrade, as well as working capital and other general corporate purposes.CITIC Securities (Hong Kong) and CMB International Capital are the joint sponsors of the offering. The two also act as overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers together with CCB International Capital.Meanwhile, CLSA Limited, Soochow Securities International Brokerage, Shenwan Hongyuan Securities (H.K.), SPDB International Capital, SDICS International Securities (Hong Kong), ICBC International Securities, Central China International Securities, BOCOM International Securities, ABCI Capital, and Guosen Securities (HK) Brokerage were tapped as joint bookrunners and joint lead managers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}